SUDAFED SINUS & ALLERGY OTC
Generic Name and Formulations:
Chlorpheniramine maleate 4mg, pseudoephedrine HCl 60mg; per tab.
McNeil Consumer Healthcare
Indications for SUDAFED SINUS & ALLERGY:
Rhinorrhea, nasal congestion, allergy symptoms.
1 tab every 4–6 hours as needed; max 4 doses/24hrs.
<6yrs: individualize. 6–11yrs: ½ tab every 4–6 hours as needed; max 4 doses/24hrs.
Within 14 days of MAOIs.
Cardiovascular disease. Hypertension. Thyroid disease. Glaucoma. Diabetes. GI or GU obstruction. Asthma. Lower respiratory disorders.
Antihistamine + sympathomimetic.
Hypertensive crisis with MAOIs. β-blockers may increase pressor response of sympathomimetics. Alcohol, other CNS depressants potentiated. Antagonizes antihypertensives.
Drowsiness, anticholinergic effects, nervousness, dizziness, insomnia, excitability in children.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Examining the Efficacy of Different Oxygen Flow Rates for Cluster Headache Attacks
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds